



Integra LifeSciences to Present At Two Conferences in September

PLAINSBORO, N.J., Sep 1, 2008 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at two conferences in September.

On Thursday, September 4 at 10:20 AM, John B Henneman III, Executive Vice President, Finance and Administration, and Chief Financial Officer of Integra LifeSciences Corporation will be presenting at the Thomas Weisel Partners Healthcare Conference at the Four Seasons in Boston, MA.

On Thursday, September 25 at 11:30 AM, Stuart Essig, President and Chief Executive Officer of Integra LifeSciences Corporation will be presenting at the UBS Global Life Sciences Conference at the Grand Hyatt in New York, NY.

Both presentations will have a live webcast. Webcasts of the presentations will be accessible through a link provided in the Investor Relations section of Integra's website at <http://www.integra-LS.com>. Additionally, a replay will be available for two weeks following the live event.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-G

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President
Finance and Administration, Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com
Karen Mroz-Bremner, Senior Manager,
Corporate Development and Investor Relations
(609) 936-6929
karen.mroz-bremner@integra-LS.com

(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX